Pathologic Damage in MS Assessed by Diffusion-Weighted and Magnetization Transfer MRI
Neurol 54:1139-1144, Cercignani,M.,et al, 2000
Progressive Cerebral Atrophy in MS
Neurol 54:807-812,782, Fox,N.C.,et al, 2000
Poliomyelitic-Like Illness in Central European Encephalitis
Neurol 55:299-302, Schellinger,P.D. et al, 2000
Optic Neuritis in Multiple Sclerosis: An Update
The Neurologist 6:205-213, Chan,J.W., 2000
Disability in Young People and Adults One Year after Head Injury: Prospective Cohort Study
BMJ 320:1631-1635, Thornhill,S. et al, 2000
Open-Ring Imaging Sign
Neurol 54:1427-1433, Masdeu,J.C.,et al, 2000
Practice Parameter: The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients With Suspected Multiple Sclerosis (an Evidence-Based Review)
Neurol 54:1720-1725, Gronseth,G.S.&Ashman,E.J., 2000
Neurologic and Developmental Disability After Extremely Preterm Birth
NEJM 343:378-384,429, Wood,N.S. et al, 2000
Functional Outcomes After Gamma Knife Thalamotomy for Essential Tremor and MS-Related Tremor
Neurol 55:443-446, Niranjan,A. et al, 2000
Diagnostic Criteria for Primary Progressive Multiple Sclerosis: A Position Paper
Ann Neurol 47:831-835, Thompson,A.J.,et al, 2000
Heterogeneity ofMultiple Sclerosis Lesions: Implications for the Pathogenesis of Demyelination
Ann Neurol 47:707-717, Lucchinetti,C.,et al, 2000
Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000
Glossopharyngeal Neuralgia and MS
Neurol 54:1368-1370, Minagar,S.&Sheremata,W.A., 2000
Outcome of Surgery for Thoracic Outlet Syndrome in Washington State Workers' Compensation
Neurol 54:1252-1257, Franklin,G.M.,et al, 2000
Multiple Sclerosis and Antecedent Infections
Neurol 54:2307-2310, Marrie,R.A.,et al, 2000
Trauma Does Not Precipitate Multiple Sclerosis
Arch Neurol 57:1077-1078, Cook.S.D., 2000
Trauma to the Central Nervous System May Result in Formation or Enlargement of Multiple Sclerosis Plaques
Arch Neurol 57:1074-1076,1078, Poser,C.M., 2000
Multiple Sclerosis--From Probable to Definite Diagnosis
Arch Neurol 57:974-979,930, Achiron,A. & Barak,Y., 2000
Psychological Stress and the Subsequent Appearance of New Brain MRI Lesions in MS
Neurol 55:55-61, Mohr,D.C. et al, 2000
Acute Aphasia in Multiple Sclerosis
Arch Neurol 57:1207-1209, Devere,T.R. et al, 2000
Health-Related Quality of Life in Neurology
Arch Neurol 57:1224-1227, Meyers,A.R. et al, 2000
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Cerebral Infarctin in the Term Newborn: Clinical Presentation and Long-Term Outcome
J Pediatr 137:351-355, Sreenan,C. et al, 2000
Relapses and Progression of Disability in Multiple Sclerosis
NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000
Multifocal Motor Neuropathy Improved by IVIg
Neurol 55:1256-1262,1246, Federico,P.,et al, 2000
Multiple Sclerosis
NEJM 343:938-952, Noseworthy,J.H. et al, 2000
Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis
NEJM 343:898-904, Jacobs,L.D. et al, 2000
A 44-Year-Old Woman with Difficulty Walking
JAMA 284:2632-2639, Iezzoni,L.I., 2000
Neurosyphilis as a Cause of Facial and Vestibulocochlear Nerve Dysfunction: MR Imaging Features
AJNR 21:1673-1675, Smith, M.M. & Anderson, J.C., 2000
Isolated Cranial Nerve Palsies Due to Brainstem Lesions
Muscle & Nerve 22:1168-1176, Thomke,F., 1999
Multiple Sclerosis That is Progressive From the Time of Onset, Clinical Characteristics and Progression of Disability
Arch Neurol 56:1138-1142, Andersson,P.B.,et al, 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Suppression of Pendular Nystagmus by Smoking Cannabis in a Patient with Multiple Sclerosis
Neurol 53:2209-2210, Schon,F.,et al, 1999
Gastric Tolerance of High-Dose Pulse Oral Prednisone in Multiple Sclerosis
Neurol 53:2093-2096, Metz,L.M.,et al, 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Musculoskeletal and Neurologic Outcomes in Patients with Previously Treated Lyme Disease
Ann Int Med 131:919-926, Shadick,N.A.,et al, 1999
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Rehabilitation of Persons With Traumatic Brain Injury
JAMA 282:974-983,989, NIH Consensus Development Panel on Rehab with TBI, 1999
Neurologic Complications in Children with Enterovirus 71 Infection
NEJM 341:936-942, Huang,C-C.,et al, 1999
Treatment Recommendations for Interferon-B in Multiple Sclerosis
JNNP 67:561-566, Polman,C.H.,et al, 1999
General Neurologist and Subspecialist Care for Multiple Sclerosis, Patients' Perceptions
Neurol 53:1190-1197, Vickrey,B.G.,et al, 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Interferon-B-1a in Relapsing-Remitting Multiple Sclerosis:Effect on Hypointense Lesion Volume on T1 Weighted Images
JNNP 67:579-584, Gasperini,C.,et al, 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
The Contribution of Magnetic Resonance Imaging to the Diagnosis of Multiple Sclerosis
Neurol 53:448-456, Fazekas,F.,et al, 1999
Optic Neuritis as Onset Manifestations of Multiple Sclerosis
Neurol 53:473-478, Sorensen,T.L.,et al, 1999
Association of MS with Thyroid Disorders
Neurol 53:883-885, Karni,A.&Abramsky,O., 1999
Evidence of Interferon B-1a Dose Response In Relapsing-Remitting MS, The OWIMS Study
Neurol 53:679-686, The Once Weekly Interferon for MS Study Group (OWI, 1999
Olfactory Dysfunction in Multiple Sclerosis:Relation to Longitudinal Changes in Plaque Numbers in Central Olfactory Structures
Neurol 53:880-882, Doty,R.L.,et al, 1999
Isolated Trochlear Nerve Palsy in Patients with Multiple Sclerosis
Neurol 53:877-879, Jacobson,D.M.,et al, 1999